The Quantellect read.As of Nov 19, 2026, 4 active firms cover Aprea Therapeutics Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $1.20 to $5.00 (about 4.2x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $2.80 sits 498% above the current $0.47. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees revenue growth near -100% this year and 0% next, consensus EPS building from about $-0.13 next quarter toward $-0.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$2.80
+497.5% upside
Average target across 4 active firms as of Nov 19, 2026 vs $0.47 current
Highest Target$5.00
Average Target$2.80
Lowest Target$1.20
Detailed analyst forecasts for APRE
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate APRE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
APRE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.13
Range $-0.13 – $-0.13 · 1 analysts · -41% YoY
Next period, 1 analysts expect Aprea Therapeutics Inc to earn $-0.13 a share (range $-0.13 – $-0.13), versus $-0.22 a year earlier. Full-year consensus is $-0.39, growing to $-0.44 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Aprea Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on APRE.
#1
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$1.20+156.1% to target
Overall win rate
34%
+ Follow
#2
Robert Driscoll
Wedbush · Rank #490
Buy
$3.00+540.2% to target
Overall win rate
32%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #567
Buy
$5.00+967.0% to target
Overall win rate
30%
+ Follow
#4
KD
Kevin DeGeeter
Ladenburg Thalmann
Buy
$2.00+326.8% to target
Coverage
—
+ Follow
#5
Matthew Biegler
Oppenheimer
Buy
$5.00+967.0% to target
Coverage
—
+ Follow
APRE stock forecast FAQ
What is APRE's average 12-month price target?+
The 4 active firms with a live target average $2.80 for Aprea Therapeutics Inc over the next 12 months, ranging from a $5.00 high to a $1.20 low, as of Nov 19, 2026.
Is APRE stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for APRE?+
The Street-high target is $5.00 (Oppenheimer), and the Street-low is $1.20 (HC Wainwright & Co.). The average of all 4 active-firm targets is $2.80.
How many active Wall Street firms cover APRE?+
4 active firms have a recognized rating on Aprea Therapeutics Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering APRE?+
Among analysts who currently cover APRE, Joseph Pantginis of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #373). Their current call is Buy with a $1.20 target.
What is Aprea Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.13 per share (range $-0.13 – $-0.13) across 1 analysts. Full-year EPS is projected at $-0.39, rising to $-0.44 the following year.
How much revenue is Aprea Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading APRE lately?+
As of Nov 19, 2026, 4 of 4 active firms rate APRE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their APRE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.